Showing results (1-10 of 667) with videos related to
Sort By:
Pageof 67
Diabetes Research and Clinical Practice|February 1, 1985
The normal range of the plasma immunoreactive glucagon level during a 75 g oral glucose tolerance testK Shima, M Hirota, K Nakamura, et al.Regulatory Peptides|August 1, 1988
Effect of glucagon-like peptide-1 on insulin secretionK Shima, M Hirota, C OhboshiAnnals of Clinical Biochemistry|March 1, 1989
Identification of glucagon-like peptide-1(7-36) amide in rat brainS Yoshimoto, M Hirota, C Ohboshi, et al.Clinical Chemistry|October 1, 1986
Determination of urinary lysozyme for potential detection of tubular dysfunction in diabetic nephropathyK Shima, M Hirota, M Fukuda, et al.Regulatory Peptides|May 1, 1988
Comparison of half-disappearance times, distribution volumes and metabolic clearance rates of exogenous glucagon-like peptide 1 and glucagon in ratsI Oshima, M Hirota, C Ohboshi, et al.Gastroenterologia Japonica|April 1, 1987
Effects of gut hormones on bile acid uptake and release in cultured rat hepatocytesI Shimizu, M Hirota, M Matsumura, et al.Endocrinology|September 1, 1987
Identification and localization of glucagon-like peptide-1 and its receptor in rat brainI Shimizu, M Hirota, C Ohboshi, et al.Endocrinologia Japonica|June 1, 1981
Exaggerated response of plasma glucagon-like immunoreactivity (GLI) to oral glucose in patients with reactive hypoglycemiaK Shima, M Tabata, A Tanaka, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|August 31, 1987
A large molecular form of glucagon-like peptide-1 (GLP-1) immunoreactivity is co-released with glucagon from pancreas by arginine in normal subjectsM Hirota, I Shimizu, C Ohboshi, et al.Diabetes Research and Clinical Practice|May 1, 1987
Effect of poly(ADP-ribose) synthetase inhibitor administration to streptozotocin-induced diabetic rats on insulin and glucagon contents in their pancreasK Shima, M Hirota, M Sato, et al.Pageof 67